Alexander I. Spira, MD, PhD, FACP, discusses the adagrasib in patients with non–small cell lung cancer in the phase 2 KRYSTAL-1 trial.
Alexander I. Spira, MD, PhD, FACP, research institute director, Thoracic and Phase 1 Trial Program, Virginia Cancer Specialists Research Institute, Virginia Cancer Specialists, clinical assistant professor, Johns Hopkins University, discusses the adagrasib (MRTX 849) in patients with non–small cell lung cancer (NSCLC) in the phase 2 KRYSTAL-1 trial (NCT03785249).
Adagrasib is currently being examined in the registrational phase 2 trial in patients with advanced/metastatic NSCLC whose tumors harbor a KRAS G12C mutation.
Adagrasib elicited a 43% response rate with a duration of response of approximately 8.5 months, Spira says. Although some patients received dose reductions, the KRAS inhibitor was well tolerated, with only 7% of patients discontinuing treatment, Spira explains.
Adagrasib is not yet approved, but it is hoped that by the end of 2022 it will be, making it the second treatment option available for patients with this mutation, Spira continues. Additional data coming out in the future focus on determining the most beneficial treatment for this patient population, Spira adds. Overall, all patients with NSCLC must be tested for mutations, especially KRAS G12C, Spira concludes.